This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase) injection, for subcutaneous use, is a HER2/neu receptor antagonist.
It is indicated for use in combination with chemotherapy as neoadjuvant treatment (this is the treatment given as a first step) of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer, adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence, and in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
If a patient becomes pregnant while receiving Phesgo or within 7 months following the last dose of Phesgo, please immediately report pregnancy to the local Roche Adverse Event Line at
In case of any adverse events or safety queries, please contact:
If you have a scientific query related to one of Roche's products, please contact:
M-PK-00001707
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.
Please be aware that you are leaving this website.